Selected article for: "activation induce and SARS cov"
Author: Molina-Cerrillo, Javier; Marquet-Palomanes, Juan; Alonso-Gordoa, Teresa; López-Jiménez, Javier; Grande, Enrique
Title: May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia
  • Cord-id: wqbr6j8v
  • Document date: 2021_1_15
    • ID: wqbr6j8v
    Snippet: COVID-19 is affecting many countries all around the world. Unfortunately, no treatment has already been approved for the management of patients infected by SARS-CoV-2. It seems that SARS-CoV-2 can induce the activation of an exaggerated immune response against itself according to different mechanisms that are not really well known. Inflammatory interleukins, such as IL-6 among others, play a central role in this uncontrolled immune response. There is a strong rational under ibrutinib use in in t
    Document: COVID-19 is affecting many countries all around the world. Unfortunately, no treatment has already been approved for the management of patients infected by SARS-CoV-2. It seems that SARS-CoV-2 can induce the activation of an exaggerated immune response against itself according to different mechanisms that are not really well known. Inflammatory interleukins, such as IL-6 among others, play a central role in this uncontrolled immune response. There is a strong rational under ibrutinib use in in the treatment of immune-based diseases, such a as GVHD or RA. Ibrutinib achieves a reduction in the production of TNFα, IL1, IL-6 and Monocyte chemo-attractant protein-1 (MCP-1) by neutrophils and macrophages, that are key players in keeping the inflammatory process. We present our clinical experience about ibrutinib use in ARDS secondary to SARS-CoV-2 in a patient with chronic lymphocytic leukemia (CLL).

    Search related documents:
    Co phrase search for related documents
    • action mechanism and adaptive immune system: 1
    • action mechanism and adhesion migration: 1, 2
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and lung capacity: 1
    • action mechanism and lung damage: 1, 2, 3, 4, 5, 6
    • action mechanism and lymphocytic leukemia: 1
    • action mechanism and macrophage neutrophil: 1
    • acute ards respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adhesion migration: 1
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and lung capacity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and lymphocytic leukemia: 1
    • acute ards respiratory distress syndrome and macrophage neutrophil: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome development and lung capacity: 1
    • acute ards respiratory distress syndrome development and lung damage: 1, 2, 3
    • adaptive immune system and adhesion migration: 1
    • adaptive immune system and lung damage: 1, 2, 3
    • adaptive immune system and macrophage neutrophil: 1, 2, 3